Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAXIMAB: COVID-19 Vaccine Response in Lymphoma
NCT04918940Completed
- Sponsor
- Centre Henri Becquerel
- Start
- May 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of LVRNA021 in coronavirus disease 2019 (COVID-19), sponsored by Centre Henri Becquerel. Primary endpoint: Determination of COVID-19 vaccination immunity at 3 months. Started May 2021; status: completed.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04918940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04918940.